Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Thalidomide and its derivatives, lenalidomide and pomalidomide (also known as IMiDs), have significantly changed the treatment landscape of multiple myeloma, and the recent discovery of cereblon (CRBN) as their direct biological target has led to a deeper understanding of their complex mechanism of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Oncol
Autores principales: Dimopoulos, Konstantinos, Søgaard Helbo, Alexandra, Fibiger Munch‐Petersen, Helga, Sjö, Lene, Christensen, Jesper, Sommer Kristensen, Lasse, Asmar, Fazila, Hermansen, Niels Emil Ulrich, O'Connel, Casey, Gimsing, Peter, Liang, Gangning, Grønbæk, Kirsten
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5792743/
https://ncbi.nlm.nih.gov/pubmed/29130642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12157
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares